摘要
目的探讨非小细胞肺癌(NSCLC)患者胸水中血管内皮生长因子(VEGF)和细胞角蛋白片段21-1(CYFRA21-1)、癌胚抗原(CEA)联合测定的临床意义。方法取48例NSCLC患者治疗前胸水标本,采用酶联免疫吸附法(ELISA)测定患者VEGF、CYFRA21-1和CEA水平。结果NSCLC患者胸水中VEGF、CYFRA21-1和CEA的阳性检出率分别为52.1%、31.3%和66.7%。NSCLC患者胸水中VEGF、CYFRA21-1和CEA联合检测的阳性表达率,在不同的肿瘤细胞分化程度、临床分期及淋巴结转移和远处转移方面均有统计学差异(P<0.05或P<0.01)。结论联合检测胸水中VEGF、CYFRA21-1和CEA可提高NSCLC的检出率,更有利于监测NSCLC患者的病情。
Objective To investigate the expression of vascular endothelial growth factor(VEGF),CYFRA21-1 and carcinoembryonic antigen(CEA) in pleural effusion of the patients with non-small cell lung cancer(NSCLC) and evaluate its clinical significance.Methods ELISA assay was used to detect the expression of VEGF,CYFRA21-1 and CEA in pleural effusion of 48 patients with NSCLC.Results The positive rate of VEGF,CYFRA21-1 and CEA in the patients with NSCLC was 52.1%,31.3%and 66.7% respectively.Differentiation grade,invasive depth,clinical staging,lymphatic metastasis and distant metastasis of esophageal carcinoma were significantly correlated with the positive rate of combined detection of VEGF,CYFRA21-1 and CEA.Conclusions Combined detection of the expression of VEGF,CYFRA21-1 and CEA in pleural effusion increases the diagnosing sensitivity of NSCLC.Long term survival analysis and more specimens would be helpful for evaluating its clinical significance.
出处
《实用老年医学》
CAS
2013年第10期816-818,共3页
Practical Geriatrics
关键词
非小细胞肺癌
血管内皮生长因子
细胞角蛋白21-1
癌胚抗原
酶联免疫吸附法
non-small cell lung cancer
vascular endothelial growth factor
cytokeratin21-1
carcinoembryonic antigen
enzyme-linked immunosorbant assay
